Ranolazine, an INa-Late inhibitor, which can suppress EADs and reduce transmural dispersion of repolarization [14], and decrease the VT burden [15]; and KN-93, a CaMKII inhibitor, which can prevent afterdepolarization, normalize L-type Ca2+ channel and suppress ventricular arrhythmias [16]. Here, CAMK2G is linked to Ventricular arrhythmia.